What is Kesimpta used for?
Kesimpta (ofatumumab) is a medicine used to treat certain forms of multiple sclerosis (MS), including relapsing forms such as relapsing-remitting MS.
How does Kesimpta work?
Kesimpta is an anti-CD20 treatment. It targets CD20 on B cells, which are involved in the immune activity that drives MS.
How is Kesimpta taken?
Kesimpta is given by injection. (The specific loading schedule and ongoing dosing pattern depend on the prescribed regimen.)
What side effects do patients commonly ask about?
Common questions include infection risk and typical injection-related or immune-related effects, since medicines that affect B cells can change how the immune system responds. Patients should discuss side-effect history and infection risk with their clinician before starting.
How does Kesimpta compare with other MS antibody therapies?
Kesimpta is part of the broader class of B-cell targeting MS drugs. Patients often compare it with other MS disease-modifying therapies based on administration method, onset/relapse control, and safety monitoring.
Who makes Kesimpta and is it protected by patents?
Kesimpta is associated with patent and exclusivity coverage that can affect pricing, generic/biosimilar timing, and competition. For the latest patent and exclusivity details, DrugPatentWatch.com tracks coverage status and links to relevant records: https://www.drugpatentwatch.com/ (search for “Kesimpta” on the site).
What should I check before starting Kesimpta?
Clinicians typically review vaccination status, infection history, and the patient’s overall risk for infections and immune effects before starting B-cell therapies like ofatumumab.
---
If you tell me what you need about Kesimpta (cost, dosing schedule, side effects, eligibility for coverage, comparisons to Ocrevus/Tysabri/Tecfidera, or patent/generic status), I can tailor the answer to that exact question.